Home > Result Summaries: Compounds > bupropion Result Summaries: bupropion GSKStudy ID Phase Title Summary (Download) 01A Phase 1 Bupropion – A double-blind toxicity study. (0 citation(s)) 100006 Phase 1 See Detailed Description (1 citation(s)) 100368 phase 4 See Detailed Description (1 citation(s)) 101497 phase 3 A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once dai ... (0 citation(s)) 101969 Phase 1 Title A Study to Evaluate the Effect of Repeated Oral Doses of WELLBUTRIN XL Compared with Placebo and Single Oral Doses of Moxifloxacin on Cardiac Conduction as assessed by 12-lead Electrocardiogram (0 citation(s)) 103104 Phase 1 A randomized, crossover, 3-period, 2-way interaction study to evaluate potential drug interactions between WELLBUTRIN XL® and citalopram in healthy volunteers (0 citation(s)) 103106 Phase 1 An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers (0 citation(s)) 105695 Phase 2 A Post-Marketing Surveillance (PMS) to monitor the safety of Wellbutrin SRTM (bupropion sustained-release) administered in Korean subjects according to the prescribing information (0 citation(s)) 108712 Phase 1 An open-label, 2-period, sequential treatment, drug interaction study to evaluate the effect of low-dose ritonavir on buproprion pharmacokinetics in healthy volunteers (0 citation(s)) 111982 n\a Post-marketing carcinogenicity study of Bupropion (0 citation(s)) 112917 N/ GlaxoSmithKline International Bupropion Pregnancy Registry (4 citation(s)) 113272 Phase 4 Post Marketing Surveillance of Zyban-SR (Bupropion hydrochloride) in the Treatment of Nicotine Dependence Among Indian Patients (0 citation(s)) 113351 phase 3 Study AK1113351, a fixed dose study of 323U66 SR in the treatment of Major Depressive Disorder (MDD) - a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study (0 citation(s)) 113694 N/ EPIDEMIOLOGY STUDY: Preliminary Report on Bupropion in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation (1 citation(s)) 113694_3 N/A EPIDEMIOLOGY STUDY: Final Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformations (1 citation(s)) 113814 n\a Zyban PEM study (0 citation(s)) 114592 n\a Bupropion and specific cardiovascular malformations (0 citation(s)) 115433 n\a Bupropion and Cardiac Birth Defects (Slone Epidemiology Center) (0 citation(s)) 11UK Phase 1 Comparison of the effects of bupropion, dextroamphetamine and amitriptyline on human performance tests, autonomic responses, EEG and subjective rating scales. (0 citation(s)) 13 Phase 3 Ninety-eight day, parallel, double-blind, randomized comparison of placebo, bupropion and amitriptyline (75-200mg/day) in outpatients, ages 55 and older – Extensive searching has revealed that no clinical study report is available for this study. (3 citation(s)) 14 Phase 2 Phase II Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients (0 citation(s)) 15 Phase 3 Thirteen week, parallel, double blind, randomized comparison of bupropion versus amitriptyline (75-100mg/day) in outpatients– Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citations below. (2 citation(s)) 16 Phase 3 Double-Blind Comparison of Doxepin versus Bupropion in Outpatients with a Major Depressive Disorder – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below. (1 citation(s)) 201 Phase 1 Single-Dose Bioequivalence of WELLBUTRIN® Sustained-Release Tablets Versus WELLBUTRIN Immediate-Release Tablets in Healthy Male Volunteers: A Pilot Study (0 citation(s)) 202 Phase 1 A Single-Dose Bioequivalence/Effect of Food Evaluation of WELLBUTRIN® Sustained-Release (0 citation(s)) 204 Phase 1 A single-dose bioavailability evaluation of the 50 and 100mg WELLBUTRIN sustained-release tablets in healthy male volunteers (0 citation(s)) 206 Phase 1 Steady-state bioequivalence evaluation of bupropion sustained-release and bupropion immediate-release tablets in healthy male volunteers (0 citation(s)) 207 Phase 1 A bioequivalence study of 50, 100, and 150 mg bupropion sustained-release tablets in healthy male volunteers (0 citation(s)) 21 Phase 3 Six week, parallel, double blind, randomized comparison of bupropion versus amitriptyline (75-225mg/day) in inpatients - Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citations below. (2 citation(s)) 300 Phase 3 A Multicenter Trial of Bupropion for Cocaine Dependence in Methadone-Maintained Patients – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below. (1 citation(s)) 404 Phase 3 Effect of chronic Wellbutrin SR administration on craving, withdrawal, and impairment of cognitive performance associated with nicotine abstinence. (1 citation(s)) 407 Phase 1 Pharmacokinetics and metabolism of Wellbutrin (bupropion hydrochloride) sustained-release in healthy smokers versus non-smokers. (1 citation(s)) 40UK Phase 1 Effect of multiple doses of bupropion on antipyrine disposition in healthy volunteers. (0 citation(s)) 40UKA Phase 1 The disposition of bupropion and its basic metabolites in young and elderly healthy volunteers. (0 citation(s)) 48 Phase 3 Cardiovascular effects of Bupropion in Depressed Patients with Heart Disease.Extensive searching has revealed that no clinical study report is available for this study. (1 citation(s)) 49 Phase 3 Cardiovascular effects of Bupropion in Depressed Patients with Heart Disease.Extensive searching has revealed that no clinical study report is available for this study. (1 citation(s)) 54 Phase 3 Disposition of Bupropion in Healthy volunteers and subjects with alcoholic liver disease. Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below. (1 citation(s)) 58 Phase 3 A Double-Blind, Placebo-Controlled Trial of Bupropion SR for SSRI-Induced Sexual Dysfunction – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below. (1 citation(s)) 75 Phase 3 Six-week, multicenter, double-blind, randomized, parallel comparison of the efficacy and safety of bupropion versus placebo in children with attention deficit disorder – Extensive searching has revealed that no clinical study report is available for this study. (2 citation(s)) 82 Phase 1 The disposition of bupropion and its metabolites in healthy male volunteers after administration of single and multiple doses of bupropion. (0 citation(s)) 83 Phase 3 Treatment of Bulimia with Bupropion: A Multicenter Controlled Trial – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below. (1 citation(s)) 88 Phase 3 Double-Blind Comparison of Bupropion and Fluoxetine in Depressed Outpatients – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below. (1 citation(s)) 89 Phase 3 Six-week, parallel, double-blind, randomized comparison of bupropion and trazodone (150-400mg/day) in outpatients – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citations below. (2 citation(s)) 9 Phase 2 Phase II double-blind evaluation of safety and efficacy of two dose ranges of bupropion vs. placebo in depressed outpatients (0 citation(s)) 90 Phase 3 The Cardiovascular Effects of Bupropion and Nortriptyline in Depressed Outpatients – Extensive searching has revealed that no clinical study report is available for this study. The clinical trial results were reported via publication; see citation below. (1 citation(s)) 96 Phase 1 Steady-State Pharmacokinetics of Two Daily Oral Doses of Wellbutrin and Its Basic Metabolites in Normal Volunteers (0 citation(s)) AK110016 Phase 4 Final study report for a randomized, single-dose, three-way crossover study examining the bioequivalence of a reformulated WELLBUTRIN SR 100 mg tablet formulation versus the currently-marketed WELLBUTRIN SR 100 mg tablet formulation in healthy volunteers. (0 citation(s)) AK110021 Phase 1 Single-Center, Randomized, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Safety of Multiple Fixed Doses of WELLBUTRIN SR (bupropion hydrochloride sustained release) Tablets in Outpatients with Untreated Stage I Hypertension (1 citation(s)) AK110022 Phase 1 An open-label, randomized, single-dose, two-way crossover study examining the bioequivalence of one newly formulated WELLBUTRIN SR† 200mg tablet versus two currently marketed WELLBUTRIN SR 100mg tablets in healthy volunteers. (0 citation(s)) AK1102364 Phase 2 Clinical evaluation of 323U66 SR in patients with depression - Open-Label study - (0 citation(s)) AK1102365 Phase 3 Clinical evaluation of 323U66 SR in patients with depression - Placebo-controlled, double-blind, comparative study in patients with depression who did not respond sufficiently to selective serotonin re-uptake inhibitors (0 citation(s)) AK1102369 Phase 2 Clinical Evaluation of 323U66 SR in patients with Depression – Investigation in Elderly patients with Depression – (0 citation(s)) AK130926 Phase 3 A Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period (2 citation(s)) AK130927 Phase 3 A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period (2 citation(s)) AK130930 phase 3 See Detailed Description (19 citation(s)) AK130931 Phase 3 See Detailed Description (3 citation(s)) AK130934 phase 3 An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder (2 citation(s)) AK130936 Phase 3 See Detailed Description (2 citation(s)) AK130939 phase 3 A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg - 300mg once daily), Extended-Release Venlafaxine Hydrochloride (75mg - 150mg once dai ... (0 citation(s)) AK130940 phase 3 A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (150mg-300mg once daily) in Elderly Subjects with Major Depressive Disorder (0 citation(s)) AK140016 Phase 4 An eight-week double-blind study comparing the effects of 20 mg of paroxetine to 150 mg of Wellbutrin SR in patients with Major Depressive Disorder (0 citation(s)) AK1A1001 Phase 1 A randomized, crossover study to evaluate the pharmacokinetic effect of cimetidine on WELLBUTRIN (Bupropion HCl) sustained release in healthy subjects. (0 citation(s)) AK1A1003 Phase 4 An open-label, 30 day study to investigate the potential pharmacokinetic interaction of multiple doses (300mg/day) of WELLBUTRIN SR (bupropion hydrochloride) on single doses (50mg) of desipramine in normal volunteers designated extensive metabolizers via the CYP2D6 pathway. (0 citation(s)) AK1A4001 Phase 4 A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCI) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression (1 citation(s)) AK1A4002 Phase 4 A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression (1 citation(s)) AK1A4003 Phase 4 A Multicenter, Double-Blind, Randomized Pilot Study Comparing the Safety and Efficacy of Wellbutrin (Bupropion HCl) Sustained Release and Paroxetine in the Treatment of Elderly Outpatients with Moderate to Severe Recurrent Major Depression (1 citation(s)) AK1A4004 Phase 4 A Multicenter Placebo-Controlled Study of WELLBUTRIN (Bupropion Hydrochloride) Sustained Release (SR) for the Prevention of Relapse/Recurrence in Subjects Whose Depression Responded to Treatment With WELLBUTRIN SR (1 citation(s)) AK1A4005 Phase 3 A Multicenter Evaluation of Wellbutrin (Bupropion Hydrochloride) Sustained Release, Habitrol (Nicotine Transdermal System), and Combination Wellbutrin Sustained Release/Habitrol Treatment Versus Placebo as Aids to Smoking Cessation. (1 citation(s)) AK1A4006 Phase 4 A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression (0 citation(s)) AK1A4007 Phase 4 A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression (1 citation(s)) AK1A4008 Phase 4 A Multi-Centre, Parallel, Randomised, Open-label, 1-Year Evaluation of the Effects of Zyban [bupropion hydrochloride sustained release tablets – BUP(SR)] and Nicorette DS (nicotine polacrilex double strength) as Aids to Smoking Cessation in Adult Chronic Cigarette Smokers (0 citation(s)) AK1A4010 Phase 4 A Parallel, Randomized, Double-Blind, Placebo-Controlled, 1-Year Pilot Study of the Effects of ZYBAN† (Bupropion Hydrochloride Sustained Release Tablets) as an Aid to Smoking Cessation in Adult Cigarette Smokers Who are Not Motivated to Quit Smoking (0 citation(s)) AK1A4011 Phase 4 An open-label study to evaluate Zyban as an aid to smoking cessation treatment in adult smokers receiving Medicaid. (1 citation(s)) AK1A4013 Phase 4 A multicenter evaluation of the effects of Zyban (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: treatment phase.ZYBAN is a registered trademark of the GlaxoSmithKline group of companies. (1 citation(s)) AK1A4013_1 Phase 4 A multicenter evaluation of the effects of Zyban™ (bupropion hydrochloride sustained release tablets) versus placebo in a population of smokers with COPD: Follow-up phase.ZYBAN is a registered trademark of the GlaxoSmithKline group of companies. (1 citation(s)) AK1A403 Phase 3 A multicenter dose response evaluation of Wellbutrin† (Bupropion hydrochloride) sustained release versus placebo as an aid to smoking cessation. (1 citation(s)) AK1A406 Phase 3 A multicenter comparison of bupropion hydrochloride sustained-release versus placebo for the prevention of relapse in patients who quit smoking while taking bupropion sustained-release (1 citation(s)) AK1B1001 Phase 1 The pharmacokinetics and tolerability of Wellbutrin SR after oral administration of a single 150 mg dose in patients with liver cirrhosis and healthy volunteers. (0 citation(s)) AK1BIOVAIL2526 Phase 1 A pilot, one-period, three-way, cross-over, steady state, open-label, multiple-dose, fasting, comparative bioavailability study of two formulations of bupropion hydrochloride extended release tablets ( 300mg q.d.) versus WELLBUTRIN™ tablets ( 100mg b.i.d. and t.i.d.) in normal healthy… (0 citation(s)) AK1BIOVAIL2543 Phase 1 A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCI 300mg extended release tablets (1 X 300mg q.d.) versus WELLBUTRIN 100mg tablets (t.i.d.) in normal healthy non-smoking male and female subjects (0 citation(s)) AK1BIOVAIL2544 Phase 1 A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCl 300 mg extended release tablets (300 mg q.d.) versus Wellbutrin 100 mg tablets (t.i.d.) in normal healthy non- smoking male and female subjects (0 citation(s)) AK1BIOVAIL2548 Phase 1 A two-way, crossover, open-label, single dose, food-effect, comparative bioavailability study of bupropion HCI extended release 300mg tablets in normal healthy non-smoking male and female subjects (0 citation(s)) AK1BIOVAIL2571 Phase 1 A two-way, crossover, open-label, single-dose, fasting, dosage strength equivalency study of two strengths (150mg and 300mg) of bupropion HCI extended release tablets given once daily in normal healthy non-smoking male and female subjects (0 citation(s)) AK1BIOVAIL2572 Phase 1 A two-way, steady state, crossover, open-label, multiple-dose, fasting, comparative bioavailability study of bupropion HCI 300 mg extended-release tablets versus ZYBAN† 150 mg tablets in normal healthy non-smoking male and female subjects. (0 citation(s)) AK1BIOVAIL2573 Phase 1 A four-way, crossover, open-label, single-dose, fasting and food effect, comparative bioavailability study of bupropion HCl extended-release 150mg tablets and Zyban 150mg tablets in normal healthy non-smoking male and female subjects (0 citation(s)) AK1BIOVAIL2594 Phase 1 A four-period, four-treatment, crossover, open-label, single-dose, fasting, in-vitro/in-vivo correlation pharmacokinetic study of three formulations of bupropion HCl extended release 150 mg tablets (fast release, target release and slow release formulations) and bupropion HCl 100 mg oral solutio ... (0 citation(s)) AKIA401 Phase 2 A single-center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation in heavy smokers (study 401) (0 citation(s)) B04-689PK-P05P2 Phase 1 A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects. (0 citation(s)) B04-696PK-P05P2 Phase 1 A two-way, steady-state, fasting, dosage form proportionality study of 150 mg Wellbutrin XL™ tablets and 450 mg bupropion extended-release tablets in normal healthy non-smoking male and female subjects. (0 citation(s)) Bupropion Suicidality Analyses Phase 4 Ongoing analysis of data in bupropion clinical trials for suicidality (0 citation(s)) Bupropion Suicidality Re-Analyses Phase 4 Re-analysis of data in bupropion clinical trials for suicidality (0 citation(s)) India - Zyban Phase 4 Post Marketing Surveillance of Zyban-SR (Bupropion hydrochloride) in the Treatment of Nicotine Dependence Among Indian Patients (0 citation(s)) KGW111083 phase 1 A double-blind, randomized, 6-sequence, 3-period crossover drug-drug interaction study to evaluate the pharmacokinetics of WELLBUTRIN SR (bupropion) and GSK189075 when co-administered or administered alone in healthy male volunteers (0 citation(s)) OHB10001 Phase 1 An open label positron emission tomography study to evaluate dopamine transporter occupancy, as measured by 11C-bCIT-FE following 150mg WELLBUTRIN SR twice daily for 8 days, in healthy male volunteers. (1 citation(s)) P02-027 Phase 1 A Single Dose Metabolism Study of 14C-Wellbutrin in Normal Volunteers (0 citation(s)) P02-24 Phase 1 Phase I - A comparison of bupropion, dextroamphetamine and placebo for abuse liability in amphetamine abusers (1 citation(s)) P02-31UK Phase 1 Examination of Bupropion and Ethanol, Alone and in Combination, on Human Performance Tests, Subjective Rating Scales, EEG and Autonomic Responses (1 citation(s)) P02-36UK Phase 1 Investigation of the Effects of Bupropion and Imipramine on the Blood Pressure Response to Tyramine in Man (0 citation(s)) P02-37UK Phase 1 Comparison of the Effects of Bupropion, Nomifensine, and Dextroamphetamine on Performance Tests, Subjective Scales, Autonomic Responses, and Electroencephalograms in Healthy Human Volunteers (1 citation(s)) RES10983 Phase 1 Double blind, randomised, placebo controlled, three periods, crossover study to investigate in a 72 hours enforced smoking cessation severity of withdrawal symptoms and craving in healthy volunteers on Zyban. (2 citation(s)) SMK20001 Phase 2 A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation. (0 citation(s)) THRS/79/0010 (Well 18) Phase 1 Examination of bupropion and diazepam, alone and in combination on human performance tests, subjective rating scales, EEG and autonomic responses. (1 citation(s)) THRS/81/0012 (Well 07B) Phase 1 Pharmacokinetics in normal volunteers. (0 citation(s)) THRS/81/0023 (Well 20UK) Phase 1 Effects of low doses of bupropion on plasma prolactin and growth hormone in normal subjects. (0 citation(s)) THRS/91/0011 (UK19) Phase 1 An Evaluation of the Bioavailability of 250 mg LAMICTAL® Tablets in Normal Volunteers (0 citation(s)) THRS/91/0023 (UK72) Phase 1 Lamotrigine Pharmacokinetics in Healthy Elderly Volunteers (0 citation(s)) US01B Phase 1 Wellbutrin: Preliminary pharmacokinetics (0 citation(s)) WELL 029 Phase 2 Multicenter Evaluation of the Efficacy and Safety of Low Doses of Wellbatrin vs. Placebo in Depressed Inpatients (0 citation(s)) Well 08 Phase 2 Phase II Placebo-Controlled Evaluation of Efficacy: Multiclinic Study (1 citation(s)) WELL 203 Phase 2 A Multicenter Evaluation of the Safety and Efficacy of 150mg/day and 300mg/day of Bupropion HCl Sustained-Release Versus Placebo in Depressed Outpatients (1 citation(s)) WELL 205 Phase 2 A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients (0 citation(s)) WELL 208 Phase 3 Safety Surveillance Study for WELLBUTRIN® (bupropion hydrochloride) Sustained Release (1 citation(s)) Well 209 Phase 3 The Safety and Efficacy of Wellbutrin Sustained Release and Sertraline in Depressed Outpatients (1 citation(s)) WELL 212 Phase 2 A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients (1 citation(s)) Well 41 Phase 2 A Single-Blind Pilot Study of the Safety and Efficacy of Wellbutrin in Children with Attention Deficit and/or Conduct Disorders (2 citation(s)) Well 84A Phase 3 Multicenter evaluation of the efficacy and safety of a 300 mg daily dose of Wellbutrin versus placebo in depressed outpatients (1 citation(s)) Well 86A Phase 4 Prospective open evaluation of the seizure incidence with bupropion hydrochloride (Wellbutrin®) (1 citation(s)) Wellbutrin 06 Phase 2 Phase II Placebo-Controlled Proof of Efficacy, Multi-clinic Study (0 citation(s)) Wellbutrin 25 Phase 3 Multicenter Evaluation of the Efficacy and Safety of Bupropion vs. Placebo in Depressed Inpatients (0 citation(s)) WXL108709 phase 1 A cross-over study to evaluate the effect of WELLBUTRIN XL on intraocular pressure in healthy volunteers (0 citation(s)) ZYB 30011 Phase 3 A multicentre, randomised, double- blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release (2 x 150mg per day) versus placebo as an aid to smoking cessation in smokers with at least one cardiovascular (CV) risk factor. (0 citation(s)) ZYB30005 Phase 3 An open-label, multicentre study with general practitioners to assess efficacy and safety of Bupropion SR (2x150mg) dependent on (sub)-depression and motivation (0 citation(s)) ZYB30009 Phase 4 A multi-centre, randomised, double-blind, placebo controlled, 6 month study to evaluate the efficacy and tolerability of bupropion hydrochloride sustained release tablets for the treatment of nicotine dependence as an aid to smoking cessation in a healthcare professionals and hospital staff popu ... (1 citation(s)) ZYB40001 Phase 4 A randomized, double-blind, placebo-controlled, 12-week smoking cessation trial of Zyban (150 mg bid) in adult smokers previously treated with Zyban (5 citation(s)) ZYB40003 Phase 4 A multicenter, randomized, parallel, placebo-controlled, one-year study of the efficacy and safety of bupropion hydrochloride sustained-release tablets versus placebo as an aid to smoking cessation treatment in adult cigarette smokers previously treated with bupropion (1 citation(s)) ZYB40005 Phase 4 The effect of sustained-release bupropion HCl vs. placebo as an aid to smoking reduction leading to cessation among smokers unwilling and unable to quit smoking (0 citation(s)) ZYB40011 Phase 4 A multi-centre, randomised, double-blind, placebo-controlled, one-year study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) (sustained release tablets) for the treatment of nicotine dependence as an aid to smoking cessation in population of healthcare professionals. (1 citation(s)) ZYB40014 Phase 4 A multi-center, randomised, parallel-group, double-blind, placebo-controlled one year study (with a 7 week Treatment Phase) to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) versus placebo as an aid to smoking cessation in a population of smokers with established, stable ... (3 citation(s)) ZYB40017 Phase 4 A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, One-Year Study to Evaluate the Efficacy and Safety of Bupropion Hydrochloride (SR) (Sustained-Release Tablets) for the Treatment of Nicotine Dependence as an Aid to Smoking Cessation. (1 citation(s)) ZYB40021 Phase 4 A 6 Month Multicenter, Randomized, Double-Blind, Pilot Study to Investigate the Tolerability and Efficacy of Bupropion SR Compared to Placebo for the Treatment of Mild Depressive Symptoms and Obesity, Followed by a 24-week Open-Label Extension (2 citation(s)) ZYB40030 Phase 4 A Multi-centre, Randomised, Double-Blind, Placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release versus placebo as an aid to smoking cessation in a population of smokers with Chronic Obstructive Pulmonary Disease. (0 citation(s)) ZYB40033 Phase 4 A multi-centre, open, one-year study to evaluate the efficacy and safety of bupropion hydrochloride (sustained release tablets) for the treatment of nicotine dependence as an aid to smoking cessation in a population of smokers either without any medical condition, with chronic obstructive pulmon ... (0 citation(s)) ZYB40036 Phase 4 A single-country, multi-centre, open-label study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) (sustained release tablets) for the treatment of nicotine dependence as an aid to smoking cessation in patients with chronic bronchitis. (1 citation(s)) ZYB40041 Phase 4 An open-label, multicentre study with general practitioners to assess efficacy and safety of Bupropion SR (2x150mg per day) as an aid to smoking cessation in patients who were previously treated with Bupropion SR or NRT (1 citation(s)) ZYB40045 Phase 4 An open one year study to evaluate the efficacy and safety of bupropion hydrochloride (Quomen) for smoking cessation in smokers with mild to moderate chronic obstructive pulmonary disease (COPD) (0 citation(s)) ZYBAKIA402 Phase 2 A single center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation (study 402) (0 citation(s)) ZYBF4001 Phase 4 Evaluation of efficacy of safety of ZybanTM (bupropion hydrochloride extended release tablet) in smoking cessation aid in nicotine-dependent patients. Multicentre, randomized, double blind, placebo-controlled study, 6 months length. (0 citation(s)) ZYBPL01 Phase 4 Efficacy and safety of Bupropion ( Zyban, GlaxoSmithKline ) for the treatment of smoking cessation in patients with chronic bronchitis. (1 citation(s))
